Derm Dispatch: Bridging Allergy and Dermatology With Zachary Rubin, MD

In the latest episode of Derm Dispatch, host Renata Block, DMSc, MMS, PA-C, spoke with board-certified allergist and New York Times bestselling author Zachary Rubin, MD, to discuss how to bridge the specialties of allergy and dermatology, debunk persistent patient misconceptions, and explore the future of atopic disease management.

Rethinking the Food-Skin Connection

One of the episode's central themes was the enduring—and potentially harmful—myth that food elimination is an effective treatment for atopic dermatitis. Rubin was direct: "Food avoidance can potentially cause more harm in the long run, especially for babies with eczema, because we know that earlier introduction and regular exposure to allergenic foods like peanuts and cow's milk can help reduce the risk of developing food allergies that could potentially be life-threatening or even persistent and lifelong."

He emphasized that meta-analyses of clinical trials show dietary elimination alone will not improve atopic dermatitis in most cases to a clinically meaningful degree, and cautioned that overreliance on food panels without corroborating clinical history can lead to false positives and unnecessary dietary restriction.

The Atopic March and the Gut-Lung-Skin Axis

Rubin walked listeners through the immunology of the atopic march, the progression from infant eczema to food allergy, allergic rhinitis, and asthma, explaining that Th2 skewing drives systemic IgE production that extends well beyond the skin. "When patients have a better understanding of how their bodies function and don't function properly, they can take that information and take better charge of their health," he said, underscoring the value of patient education in improving clinical outcomes.

Emerging Therapies and Cross-Specialty Collaboration

Looking ahead, Rubin highlighted the expanding role of Janus kinase inhibitors and novel biologics in atopic disease, including a phase 1 trial combining dupilumab with linvoseltamab, an agent approved for multiple myeloma, to potentially drive food allergy into remission by depleting IgE-producing plasma cells. He also spotlighted the underrecognized burden of indolent systemic mastocytosis, which carries a prevalence comparable to psoriasis yet remains far less visible in clinical practice.

Busting the Hypoallergenic Dog Myth

On a lighter but clinically relevant note, Rubin addressed the ubiquitous patient request for hypoallergenic dogs: "Every dog makes differing amounts [of allergens], so sometimes you can tolerate some dogs vs others, but you can't reliably predict that based [on] the label ‘hypoallergenic.’"

Block closed the episode by noting that Rubin's book, All About Allergies, is a valuable resource not just for patients but for every clinician who encounters allergic and atopic disease in practice.

Like this podcast, have suggestions, or want to participate in future episodes? Contact our team at [email protected].